Hepatocellular carcinoma: Recent progress

Hepatology

Volumn 15, Issue 5, 1992, Pages 948-963

  Okuda, Kunio ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ALCOHOL; ORAL CONTRACEPTIVE AGENT; VIRUS DNA;

ADENOMA; ARTICLE; ARTIFICIAL EMBOLISM; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME REARRANGEMENT; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALIGNANT TRANSFORMATION; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ANIMAL; CARCINOMA, HEPATOCELLULAR; CHROMOSOME MAPPING; FORECASTING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER NEOPLASMS;

EID: 0026576723     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840150532     Document Type: Article

References (242)

1. Early recognition of hepatocellular carcinoma
2. Epidemiology of hepatocellular carcinoma
3. A clinical study of hepatocellular carcinoma (HCC) in relation to hepatitis B seromarkers: implication of non‐A, non‐B hepatitis (NANB) [Abstract]
4. Increasing incidence of hepatocellular carcinoma possibly associated with non‐A, non‐B hepatitis in Japan, disclosed by hepatitis B virus DNA analysis of surgically resected cases
5. Changing incidence of hepatocellular carcinoma in Japan
6. Hepatocellular carcinoma and cirrhosis: a review of their relative incidence in a 25‐year period in the Florence area
7. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis
8. Hepatocellular carcinoma in Italian patients with cirrhosis
9. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma
10. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma
11. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis
12. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus
13. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease
14. Hepatitis C‐associated hepatocellular carcinoma
15. Prevalence of anti‐HCV antibody in blood donors in the Tokyo area
16. Antibodies to hepatitis C virus in Italian blood donors
17. Antibodies to hepatitis C virus in French blood donors
18. Epidemiology of hepatitis C virus: a preliminary study in volunteer blood donors
19. Antibodies to hepatitis C virus in patients with hepatocellular carcinoma
20. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience
21. Detection of hepatitis C ribonucleic acid in the serum by amplification with polymerase chain reaction
22. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma
23. Primary hepatocellular carcinoma after non‐A, non‐B posttransfusion hepatitis
24. Hepatocellular carcinoma after non‐A, non‐B posttransfusion hepatitis
25. Primary hepatocellular carcinoma after chronic non‐A, non‐B post‐transfusion hepatitis
26. Prevalence of chronic liver diseases and anti‐HCV antibodies in different districts of Saga, Japan
27. Hepatitis C virus and hepatocellular carcinoma
28. Hepatocellular carcinoma in hemophilia
29. Hepatitis C infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis
30. Independent risk factors for hepatocellular carcinoma in French drinkers
31. Studies on anti‐HCV in hepatocellular carcinoma with alcoholic cirrhosis (in Japanese)
32. High incidence of antibodies to hepatitis C virus in alcoholic cirrhosis: fact or fiction
33. Alcohol: a major risk factor for hepatocellular carcinoma
34. Effects of ethanol on experimental hepatocarcinogenesis
35. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage
36. Prevalence of hepatocellular carcinoma and relation to cirrhosis: comparison of two different cities of the world, Trieste, Italy, and Chiba, Japan
37. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei
38. Mutational hotspot in the p53 gene in human hepatocellular carcinoma
39. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
40. Hepatic tumors: possible relationship to use of oral contraceptives
41. Hepatoma in the noncirrhotic liver
42. Oral contraceptive‐associated liver cell adenoma and hepatocellular carcinoma: cytomorphology and mechanism of malignant transformation
43. Oral‐contraceptive—associated liver tumors: occurrence of malignancy and difficulties in diagnosis
44. Hepatocellular carcinoma in women: probable lack of etiologic association with oral contraceptive steroids
45. Estrogen induction of hepatocellular carcinoma in Armenian hamsters
46. Experimental studies on hepatocarcinogenesis induced by oral contraceptives, with special reference to estrogen receptor and the effect of tamoxifen
47. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver disease
48. Idiopathic hemochromatosis, and iron storage disease. A. Iron metabolism in hemochromatosis
49. Survival and causes of death in cirrhosis and in noncirrhotic patients with primary hemochromatosis
50. Obstruction of the inferior vena cava in the hepatic portion and the hepatic veins
51. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa
52. Primary liver cancer in the Transvaal
53. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in southern African blacks
54. Neoplasms of the liver
55. Neoplasms of the liver
56. Hepatocellular carcinoma in primary biliary cirrhosis: report of four cases
57. Hepatocellular carcinoma in primary biliary cirrhosis: detection by fetoprotein estimation
58. Hepatocellular carcinoma in primary biliary cirrhosis: an autopsy study
59. A case of an 80‐year‐old man with primary biliary cirrhosis complicated with primary hepatocellular carcinoma (in Japanese)
60. Macroregenerative nodules of the liver in primary biliary cirrhosis: report of two autopsy cases
61. Hepatocellular carcinoma in a patient with precirrhotic primary biliary cirrhosis
62. Hepatocellular carcinoma in primary biliary cirrhosis: a prospective study by serial fetoprotein testing [Abstract]
63. On the pathogenesis of experimental hepatocellular carcinoma
64. Oncogenesis, antioncogenes, and the molecular bases of multistep carcinogenesis
65. Growth factors and cancer
66. The molecular genetics of cancer
67. Detection of cellular oncogenes in spontaneous liver tumors of B6C3F1 mice
68. Detection and identification of activated oncogenes in spontaneously occurring benign and malignant hepatocellular tumors of the B6C3F1 mouse
69. Activated c‐ras gene in a rat hepatocellular carcinoma induced by 3‐amino‐3‐methylimidazo (4,5‐f) quinoline
70. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis
71. Detection of high incidence of K‐ras oncogenes during human colon tumorigenesis
72. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma
73. Low incidence of point mutation of c‐Ki‐ras and N‐ras oncogenes in human hepatocellular carcinoma
74. Analysis of ras gene mutation in human hepatic malignant tumors by polymerase chain reaction and direct sequencing
75. Transfection of oncogenes activated in human hepatocellular carcinomas
76. Transforming potential of DNA of the human PLC/PRF/5 hepatoma cell line
77. An in vivo system for infection with hepatitis B virus that uses primary human hepatocytes
78. Transformation of NIH‐3T3 cells by DNA from a human hepatoma cell line with integrated hepatitis B virus DNA
79. Genetic alterations during colorectal tumor development
80. Identification of a chromosome 18q gene that is altered in colorectal cancers
81. A genetic model for colorectal tumorigenesis
82. Regulation of liver growth: protooncogenes and transforming growth factors
83. Early changes in gene expression during liver regeneration: what do they mean
84. Sequential protooncogene expression during rat liver regeneration
85. Analysis of proto‐oncogene expression during liver regeneration and hepatocarcinogenesis
86. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary culture
87. Molecular cloning and sequence analysts of cDNA for human hepatocyte growth factor
88. Identification of the hepatocyte growth factor receptor as the C‐met proto‐oncogene product
89. 1—induced rat liver tumors
90. Mutational analysis of the H‐ras oncogene in spontaneous C57BL/6 × C3H/He mouse liver tumors and tumors induced with genotoxic and nongenotoxic hepatocarcinogens
91. Evidence in human hepatomas for structural chromosome changes and alteration in the expression of genes in the region 4q21–4q27 [Abstract]
92. Deletion in human chromosome arms 11p and 13q in primary hepatocellular carcinomas
93. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma
94. Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma
95. Allelotype study of primary hepatocellular carcinoma
96. Allele loss on chromosome 16 associates with progression of human hepatocellular carcinoma
97. Tumor suppressor genes and tumors associated with virus infection. Interaction of HPV 16 and 18 with tumor suppressor gene products
98. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma
99. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single‐strand conformation polymorphism analysis
100. Aberrations of the tumor suppressor p53 and RB genes in human hepatocellular carcinoma
101. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan
102. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis Bs and e antigen/antibody in serum: a prospective study
103. Presence of integrated hepatitis B virus DNA sequences in cellular DNA in human hepatocellular carcinoma
104. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma
105. Detection and properties of hepatitis B viral DNA in liver tissues from patients with hepatocellular carcinoma
106. Chromosomal changes associated with hepatitis B virus DNA integration and hepatic carcinogenesis
107. Sequence of hepatitis B virus DNA incorporated into the genome of a human hepatoma cell line
108. Integrated structure of duck hepatitis B virus DNA in hepatocellular carcinoma
109. Status of hepatitis B virus DNA in hepatocellular carcinoma: a study based on paired tumor and nontumor liver tissue
110. Clonal state of human hepatocellular carcinoma and non‐tumorous hepatocytes
111. Identification of a chromosomal aberration associated with a hepatitis B DNA integration site in human cells
112. Integration of hepatitis B virus: analysis of unoccupied sites
113. Features of two hepatitis B virus CHB DNA integrations suggest mechanisms of HBV integration
114. Integration of hepatitis B virus DNA in chromosome‐specific satellite sequences
115. Hypervariable minisatellite region in human DNA
116. Variable number of tandem repeat (VNTR) markers for human gene mapping
117. Genomic localization of hepatitis B virus in a human hepatoma cell line
118. Interstitial chromosomal deletion within 4q11‐q13 in a human hepatoma cell line
119. Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17; 18 translocation
120. Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma
121. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA
122. Transforming genes in human hepatomas detected by a tumorigenicity assay
123. Molecular cloning of an oncogene from a human hepatocellular carcinoma
124. A common mechanism for the malignant activation of ras oncogenes in human neoplasia and in chemically induced animal tumors
125. Activation of ras oncogene in aflatoxin‐induced rat liver carcinogenesis
126. Infrequent activation of K‐ras, H‐ras and other oncogenes in hepatocellular neoplasms initiated by methyl (acetoxymethyl) nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats
127. Activated N‐ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells
128. Transforming DNA sequences of human hepatocellular carcinoma, their distribution and relationship with hepatitis B virus sequence in human hepatomas
129. Structure and expression of hcr, a locus rearranged with c‐myc in a woodchuck hepatocellular carcinoma
130. Analysis of ras genes and linked viral sequences in rat hepatocarcinogenesis
131. Co‐amplification of integrated hepatitis B virus DNA and transforming gene hst‐1 in a hepatocellular carcinoma
132. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11‐base‐pair direct repeat
133. Inversely repeating integrated hepatitis B virus DNA and cellular flanking sequences in the human hepatoma‐derived cell line huSP
134. Integration of hepatitis B virus DNA: evidence for integration in the single‐stranded gap
135. Hepatitis B virus integration in a sequence homologous to v‐erb‐A and steroid receptor genes in a hepatocellular carcinoma
136. Identification of a second human retionoic acid receptor
137. A novel steroid thyroid hormone receptor‐related gene inappropriately expressed in human hepatocellular carcinoma
138. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
139. A liver‐specific enhancer in the core promoter region of human hepatitis B virus
140. Transactivation by hepatitis B virus may contribute to hepatocarcinogenesis
141. Transcriptional trans‐activating function of hepatitis B virus
142. Trans‐activation of viral enhancers by the hepatitis B virus S protein
143. Regulation of hepatitis B virus S gene promotor in transfected cell lines
144. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication
145. Trans‐activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus S protein
146. A transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state
147. Cotranscribed 3′ host sequences augment expression of integrated hepatitis B virus DNA
148. Hybrid hepatitis B virus‐host transcripts in a human hepatoma cell
149. Integration of region X of hepatitis B virus genome in human primary hepatocellular carcinomas propagated in nude mice
150. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator
151. Woodchuck hepatitis and hepatocellular carcinoma: correlation of histologic with virologic observations
152. Hepato‐carcinogenicity of the woodchuck hepatitis virus
153. Activation of c‐myc by woodchuck hepatitis virus infection in hepatocellular carcinoma
154. Hepadnaviruses as insertional mutagens in hepatocellular carcinoma
155. Frequent activation of N‐myc genes by hepadna virus insertion in woodchuck liver tumors
156. Duck hepatitis B virus and liver disease
157. Duck hepatitis B virus DNA in liver and serum of Chinese ducks: integration of viral DNA in a hepatocellular carcinoma
158. Integrated structures of duck hepatitis B virus DNA in hepatocellular carcinoma
159. Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus
160. Hepatocellular carcinoma in Richardson's squirrels (Spermophilus richardsonii): evidence for association with hepatitis B‐like virus infection
161. New mutation causing hereditary hepatitis in the laboratory rat
162. A rat strain that spontaneously develops severe hepatic necrosis and later hepatocellular carcinoma
163. Metabolic predisposition of a novel mutant (LEC rats) to hereditary hepatitis and hepatoma: alterations of the drug metabolizing enzymes
164. Pathological and laboratory findings in LEC/Otk rats that spontaneously develop hepatic injury
165. Peripheral neuropathies, hepatocellular carcinoma and islet cell adenoma in transgenic mice
166. Hepatocarcinogenesis in transgenic mice carrying albumin‐promoted SV40 T antigen gene
167. Early regions of JC virus and BK virus induced distinct and tissue‐specific tumors in transgenic mice
168. New murine model for hepatocellular carcinoma: transgenic mice expressing metallothionein‐ovine growth hormone fusion gene
169. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state
170. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice
171. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
172. Evolution of hepatocellular carcinoma associated with chronic hepatitis B virus infection in Alaskan Eskimos
173. Viral versus chemical hepatocarcinogenesis
174. The tat gene of human T‐lympotropic virus type 1 induced mesenchymal tumors in transgenic mice
175. HBx gene of hepatitis B virus induced liver cancer in transgenic mice
176. Characterization of hepatitis B virus X gene: in vitro translation of mRNA from Cos‐1 cells transfected with the X gene
177. Cytology and cytogenesis of neoplastic (hyperplastic) hepatic nodules
178. Precursor lesions for liver cancer in humans
179. Hepatitis B virus and primary liver cell carcinoma
180. Karyometric analysis of liver cell dysplasia and hepatocellular carcinoma: evidence against precancerous nature of liver cell dysplasia
181. Morphologic studies of the liver cell dysplasia
182. Pathology of hepatocellular carcinoma
183. Advances in hepatobiliary ultrasonography
184. Computed tomography in the evaluation of hepatocellular carcinoma
185. Infusion hepatic angiography in the detection of small hepatocellular carcinoma
186. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histology
187. Primary liver cancer in Japan. Clinico‐pathologic features and results of surgical treatment
188. Small mass lesions in cirrhosis: transition from benign adenomatous hyperplasia to hepatocellular carcinoma
189. What is the precancerous lesion for hepatocellular carcinoma in man
190. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver: observations in five cases
191. Pathologic aspects of cirrhosis. A review
192. Morphological clues for the diagnosis of small hepatocelluar carcinoma
193. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies
194. Morphometric analysis of hepatocellular carcinoma
195. Differential diagnosis of early hepatocellular carcinoma [A]
196. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma
197. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma
198. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma
199. “Atypical adenomatous hyperplasia” in liver cirrhosis: low‐grade hepatocellular carcinoma or borderline lesions
200. Histologic growth of hepatocellular carcinoma: relation to orcein (hepatitis B surface antigen)—positive cells in cancer tissue
201. Cytometric DNA analysis of adenomatous hyperplasia in cirrhotic livers
202. Progressive enlargement of an hepatic cell adenoma
203. Multiple hepatic adenomas and a hepatocellular carcinoma in a man on oral methyl testosterone for eleven years
204. Adenomatous hyperplasia of the liver
205. Liver adenomatosis: an entity distinct from liver adenoma
206. Benign epithelial tumors and tumor‐like lesions of the liver
207. Oral contraceptive‐associated‐liver cell adenoma and hepatocellular carcinoma: cytomorphology and mechanism of malignant transformation
208. Expression of ABH blood group antigens, receptors of Ulex eurogaeus agglutinin I, and factor VIII‐related antigen on sinusoidal endothelial cells in adenomatous hyperplasia in human cirrhotic livers
209. Survey of iron‐accumulative macroregenerative nodules in cirrhotic livers
210. Iron‐negative foci in siderotic macrore‐generative nodules in human cirrhotic liver: a marker of incipient neoplastic lesions
211. Hepatocellular carcinoma within siderotic regenerative nodules: appearance as a nodule within a nodule on MR images
212. Regenerating nodules in hepatic cirrhosis: MR findings with pathologic correlation
213. Minute hepatoma with excessive copper accumulation
214. MR imaging of small hepatocellular carcinoma: effect of intratumoral copper content on signal intensity
215. Hepatocellular carcinoma with excessive copper accumulation: CT and MR findings
216. Cirrhosis of the liver: regenerative process
217. Cytoplasmic hyaline inclusion in hepatoma: histochemical study
218. Small hepatocellular carcinoma containing many Mallory bodies
219. Mallory body clustering in adenomatous hyperplasia in human cirrhotic livers: report of four cases
220. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging
221. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply
222. Hepatocellular carcinoma detected by iodized oil
223. 2 microbubbles
224. Adenomatous hyperplastic nodules in the cirrhotic liver: a therapeutic approach: work in progress
225. Review of adenomatous hyperplastic nodules in liver cirrhosis: pathological features, imaging diagnosis and prognostic significance
226. Clinicopathological studies of minute hepatocellular carcinoma: Analysis of 20 cases including 4 with resection
227. Small hepatocellular carcinoma
228. Pathomorphologic characteristics of early hepatocellular carcinoma
229. Differential diagnosis of early hepatocellular carcinoma
230. Pathology of small hepatocellular carcinoma: a proposal for a new gross classification
231. Biopsy diagnosis of well‐differentiated hepatocellular carcinoma based on new morphologic criteria
232. Histological features and clinical course of large regenerative nodules: evaluation of their precancerous potentiality
233. Histological and morphometrical indicators for a biopsy diagnosis of well‐differentiated hepatocellular carcinoma
234. Clonal origin of human hepatocellular carcinoma determined by integration of hepatitis B virus DNA
235. Clonal origin of hepatitis B virus‐associated hepatocellular carcinoma
236. Hepatocellular carcinoma and hepatitis B virus infection: molecular evidence for monoclonal origin and expansion of malignantly transformed hepatocytes
237. Clonal origin of recurrent hepatocellular carcinoma
238. Multicentric independent development of hepatitis B virus integration pattern
239. Resection of hepatocellular carcinoma: oligocentric origin of recurrent and multinodular tumours
240. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules